Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBaylor Scott & White Kymriah Prior Auth | OpenPaye…
    Ask Trek AI about this page
    ModifiedBaylor Scott & White Health PlanPolicy 279

    Tisagenlecleucel (Kymriah) CAR-T therapy

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 279 alerts

    Get alerted when Policy 279 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for tisagenlecleucel (Kymriah) in members receiving CAR-T therapy. Coverage is considered for specified B-cell precursor acute lymphoblastic leukemia and B-cell lymphoma indications when universal and indication-specific criteria are met.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyTisagenlecleucel (Kymriah) CAR-T therapy
    Policy CodePolicy 279
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateSep 24, 2027
    Key ActionPrior authorization is required for tisagenlecleucel (Kymriah).
    SourceLink
    POLICY UPDATE CHANGES

    The policy added criteria requiring the prescriber to be or consult with a board-certified hematologist or oncologist and requiring appropriate candidate assessment for apheresis.

    The policy added additional follicular lymphoma criteria.

    The policy revised universal CAR-T criteria, including prescriber, dosing and administration, monotherapy, apheresis, prior CAR-T treatment, anti-CD19 treatment, and exclusion requirements.

    The policy history states that the REMS program requirement was removed.

    The policy was updated on September 24, 2026 to update coding information.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredAuthorization requirement
    1 lifetimeMaximum treatment limit
    ≤25 yearsMaximum B-ALL age
    ≥18 yearsMinimum lymphoma age
    81%ELIANA remission rate

    Medical Necessity and Coverage Criteria

    Universal Criteria

    Covered when all universal criteria are met.

    Universal criteria

    • Prescriber: Tisagenlecleucel is prescribed by or used in consultation with a board-certified hematologist or oncologist
    • Administration: Tisagenlecleucel is dosed and administered according to FDA-approved labeling
    • Therapy use: Tisagenlecleucel is used as monotherapy
    • Apheresis: The member has been assessed by a hematologist or oncologist to be an appropriate candidate for apheresis
    • CD19 expression: Documentation confirms CD19 tumor expression
    • Prior CAR-T therapy: The member has had no prior treatment with CAR T-cell immunotherapy, including axicabtagene, brexucabtagene, liscabtagene, or obecabtageneNone
    • Prior anti-CD19 therapy: If the member received prior anti-CD19 therapy, a repeat biopsy indicates CD19-positive diseaseCD19-positive repeat biopsy

      Examples of prior anti-CD19 therapy include tafasitamab, loncastuximab, and blinatumomab

    • Exclusions absent: The member does not have any listed infection or CNS disease exclusion

      No active hepatitis B, active hepatitis C, HIV infection, uncontrolled infection, or active CNS malignancy involvement with lymphoblasts and CSF white blood cell count of at least 5 cells/mcL

    B-Cell Precursor Acute Lymphoblastic Leukemia

    Covered for B-cell precursor acute lymphoblastic leukemia when all universal and indication-specific criteria are met.

    B-cell precursor acute lymphoblastic leukemia criteria

    • Universal criteria: All universal criteria are met
    • Age: The member is 25 years or younger<=25 years
    • Performance status: The member has a Karnofsky or Lansky performance score of at least 50% or an ECOG performance score of 0-3Karnofsky/Lansky >=50% or ECOG 0-3

    B-Cell Lymphoma

    Covered for B-cell lymphoma when all universal and indication-specific criteria are met.

    B-cell lymphoma criteria

    • Universal criteria: All universal criteria are met
    • Age: The member is 18 years or older>=18 years
    • Performance status: The member has an ECOG performance status of 0 or 1ECOG 0-1
    • Covered diagnosis

    Coverage excludes members with active hepatitis B, active hepatitis C, HIV infection, or an uncontrolled infection. Coverage also excludes active central nervous system malignancy involving lymphoblasts with a cerebrospinal fluid white blood cell count of at least 5 cells/mcL.

    Only one tisagenlecleucel treatment per lifetime is considered medically necessary. Repeat administration beyond this lifetime limit is excluded from coverage.

    Treatment for indications other than the specified covered uses—B-cell precursor acute lymphoblastic leukemia, relapsed or refractory large B-cell lymphoma after qualifying prior therapy, and relapsed or refractory follicular lymphoma after qualifying prior therapy—is excluded. Primary central nervous system lymphoma is specifically not an indicated use.

    Repeat administration of tisagenlecleucel is considered experimental and investigational and not medically necessary because the effectiveness of repeat treatment has not been established.

    Tisagenlecleucel used for indications other than those specified in this policy is considered experimental and investigational and not medically necessary because the effectiveness of these uses has not been established.

    Covered and Associated Codes

    CPT CodesCPT
    38225Chimeric antigen receptor T-cell (CAR-T) therapy; harvest of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day
    38226Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (e.g., cryopreservation, storage)
    38227Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preservation of CAR-T cells for administration
    38228Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous
    HCPCS CodesHCPCS
    Q2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.
    ICD-10 CodesICD-10
    C82.00-C82.99Follicular lymphoma
    C83.30-C83.39Diffuse large B-cell lymphoma
    C85.20-C85.29Primary mediastinal large B-cell lymphoma
    C91.00-C91.02Acute lymphoblastic leukemia
    D47.Z1Post-transplant lymphoproliferative disorder
    CPT CodesCPTCovered
    38228Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous
    HCPCS CodesHCPCSCovered
    Q2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
    ICD-10 CodesICD-10Covered
    C82.00-C82.99Follicular lymphoma
    C83.30-C83.39Diffuse large B-cell lymphoma
    C85.20-C85.29Primary mediastinal large B-cell lymphoma
    C91.00-C91.02Acute lymphoblastic leukemia
    D47.Z1Post-transplant lymphoproliferative disorder
    Cerebrospinal Fluid White Blood Cell Count
    ExclusionActive CNS malignancy involvement with presence of lymphoblasts
    CSF criterionCerebrospinal fluid white blood cell count of at least 5 cells/mcL
    Policy thresholdThe specified CNS exclusion applies at 5 cells/mcL or greater; the threshold value is less than 5 cells/mcL for exclusion avoidance
    B-ALL Age
    IndicationB-cell precursor acute lymphoblastic leukemia (B-ALL)
    Maximum age

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before tisagenlecleucel (Kymriah) is administered. All requests are reviewed by both a clinical pharmacist and a medical director.

    Documentation Required

    Medical Necessity Documentation

    Submit documentation supporting medical necessity for every applicable universal and indication-specific criterion. Requests may be denied when the record does not establish that all required criteria are satisfied.

    • Include clinical records, diagnostic findings, treatment history, performance status, and planned therapy details as applicable.
    Documentation Required

    Universal Clinical Documentation

    Therapy Overview

    Tisagenlecleucel is a CD19-directed, genetically modified autologous T-cell immunotherapy. The patient's peripheral blood T cells are collected through leukapheresis and prepared for administration after genetic modification to express a chimeric antigen receptor that targets CD19-expressing malignant and normal cells.

    Key Clinical Definitions

    Tisagenlecleucel Definition
    Therapy typeCD19-directed genetically modified autologous T-cell immunotherapy
    Cell sourceThe patient's peripheral blood cells obtained via leukapheresis
    Genetic modificationThe patient's T cells are reprogrammed with a transgene encoding a chimeric antigen receptor (CAR)
    TargetThe CAR identifies and eliminates CD19-expressing malignant and normal cells
    Primary Refractory or Chemorefractory B-ALL
    DiseaseB-cell precursor acute lymphoblastic leukemia
    Primary refractory disease

    Initial Treatment

    Initial Treatment

    Initial treatment requires prior authorization and satisfaction of all universal criteria plus the applicable disease-specific criteria.

    Initial treatment authorization

    • Prior authorization is approved for tisagenlecleucel

      Requests are reviewed by both a clinical pharmacist and a medical director

    • Universal criteria: All universal criteria are met
    • Covered indication

      • B-cell precursor acute lymphoblastic leukemia

        • Age:

    Continuation and Repeat Treatment

    One Treatment per Lifetime

    Repeat treatment is not covered as medically necessary.

    Lifetime treatment limit: Only one tisagenlecleucel treatment is considered medically necessary per lifetime1 lifetime treatment

    Repeat administration is considered experimental and investigational because the effectiveness of this strategy has not been established

    Lifetime Treatment Limit

    Tisagenlecleucel (Kymriah)
    DrugTisagenlecleucel (Kymriah)
    Quantity limitOne treatment per lifetime
    Repeat treatmentNot considered medically necessary; repeat administration is experimental and investigational because effectiveness has not been established
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyTisagenlecleucel (Kymriah) CAR-T therapy
    Policy CodePolicy 279
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateSep 24, 2027
    Key ActionPrior authorization is required for tisagenlecleucel (Kymriah).
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered and Associated CodesAuthorization, Documentation, and Denial RisksTherapy OverviewKey Clinical DefinitionsInitial TreatmentContinuation and Repeat TreatmentLifetime Treatment Limit
    Diagnosis:
    The member has B-cell precursor acute lymphoblastic leukemia
  1. Philadelphia chromosome-negative disease

    • Refractory disease: Primary refractory disease or chemorefractory disease

      Primary refractory disease means no complete response after 2 cycles of standard chemotherapy; chemorefractory disease means no complete response after 1 cycle of standard chemotherapy for relapsed disease

    • Relapse: Second or greater bone marrow relapse>= second bone marrow relapse
  2. Philadelphia chromosome-positive disease

    • TKI history: The member has a contraindication to, intolerance of, or failure of two prior lines of tyrosine kinase inhibitor therapy2 prior TKI lines

      Examples include imatinib, dasatinib, and ponatinib

    • Post-transplant relapse: Any bone marrow relapse occurred after allogeneic stem cell transplantationAny bone marrow relapse after allogeneic SCT
  3. Diffuse large B-cell lymphoma, not otherwise specified
  4. High-grade B-cell lymphoma
  5. Transformed lymphoma: Diffuse large B-cell lymphoma arising from follicular lymphoma
  6. Follicular lymphoma
  7. Prior therapy: Tisagenlecleucel will be used as third-line or subsequent therapyThird-line or later
  8. 25 years or younger
    RequirementThe member must meet all universal and applicable B-ALL-specific criteria
    B-ALL Performance Status
    Karnofsky performance scoreAt least 50%
    Lansky performance scoreAt least 50%
    ECOG performance score0-3
    B-Cell Lymphoma Age
    IndicationB-cell lymphoma
    Minimum age18 years or older
    Additional requirementThe member must meet all universal and applicable B-cell lymphoma-specific criteria
    B-Cell Lymphoma Performance Status
    Performance measureEastern Cooperative Oncology Group (ECOG) performance status
    Acceptable statusECOG 0 or 1
    IndicationB-cell lymphoma
    Lifetime Treatment Limit
    DrugTisagenlecleucel (Kymriah)
    Lifetime limitOne treatment per lifetime
    Repeat administrationExperimental and investigational because effectiveness of repeat treatment has not been established

    Document that the request meets all universal requirements before submitting it for review.

    • Prescribed by or in consultation with a board-certified hematologist or oncologist.
    • Dosed and administered according to FDA-approved labeling.
    • Used as monotherapy.
    • Member assessed by a hematologist/oncologist as an appropriate candidate for apheresis.
    • CD19 tumor expression documented.
    Documentation Required

    Indication-Specific Documentation

    Provide diagnosis- and indication-specific documentation establishing that the member meets the applicable B-ALL or B-cell lymphoma criteria.

    • B-ALL: member is 25 years or younger; diagnosis is B-cell precursor acute lymphoblastic leukemia; Karnofsky or Lansky performance score is ≥ 50% or ECOG is 0–3; and disease status is documented. For Ph-negative disease, document primary refractory disease, chemorefractory relapsed disease, or second or greater bone marrow relapse. For Ph-positive disease, document contraindication, intolerance, or failure of two prior TKI lines, or any bone marrow relapse after allogeneic SCT.
    • B-cell lymphoma: member is 18 years or older; ECOG performance status is 0 or 1; diagnosis is DLBCL not otherwise specified, high-grade B-cell lymphoma, DLBCL arising from follicular lymphoma, or follicular lymphoma; and tisagenlecleucel will be used as third-line or subsequent therapy.
    • Where applicable, document relapsed or refractory disease and the required prior systemic therapy history.
    Documentation Required

    Prior Therapy and Exclusion Review

    Document prior cellular and anti-CD19-directed therapy history and address all applicable exclusions. If the member previously received anti-CD19 therapy, provide repeat biopsy results demonstrating CD19-positive disease.

    • Confirm no prior CAR T-cell immunotherapy, including axicabtagene, brexucabtagene, lisocabtagene, or obecabtagene.
    • If prior anti-CD19 therapy was used, such as tafasitamab, loncastuximab, or blinatumomab, submit the repeat biopsy showing CD19-positive disease.
    • Document relevant prior chemotherapy, TKI therapy, stem cell transplantation, and treatment response or relapse status.
    Denial Risk

    Failure to Meet Clinical Criteria

    Requests are at risk for denial when any universal or indication-specific medical-necessity criterion is not met or is not supported by the submitted documentation.

    • Do not submit without documentation of the required diagnosis, age, performance status, disease status, prior treatment, CD19 expression, and applicable line-of-therapy requirements.
    • For B-ALL, document the applicable Ph-negative or Ph-positive disease pathway and qualifying treatment history.
    • For B-cell lymphoma, document an eligible histology and third-line or subsequent use.
    Denial Risk

    Excluded Infection or CNS Disease

    Tisagenlecleucel is not medically necessary when the member has a specified active infection or active CNS malignancy involvement with lymphoblasts.

    • Active hepatitis B (HBsAg-positive), active hepatitis C, HIV infection, or uncontrolled infection.
    • Active CNS malignancy involvement with lymphoblasts, defined as WBC ≥ 5 cells/mcL in the cerebrospinal fluid.
    Denial Risk

    Repeat Treatment

    BSWHP considers only one tisagenlecleucel treatment per lifetime medically necessary. Repeat administration is considered experimental and investigational because the effectiveness of repeat treatment has not been established.

    • Document treatment history to confirm that the member has not previously received tisagenlecleucel.
    Denial Risk

    Unlisted Indication

    Requests for tisagenlecleucel for indications outside the policy-defined covered diseases are considered experimental and investigational because effectiveness has not been established.

    • Covered disease categories are B-cell precursor ALL meeting the policy criteria and eligible B-cell lymphoma indications, including specified large B-cell lymphoma and follicular lymphoma.
    • Primary CNS lymphoma is not an indicated use.
    Denial Risk

    Administration Outside Policy Requirements

    Administration that does not follow the policy requirements may result in denial. Confirm that tisagenlecleucel is administered as monotherapy, at the FDA-labeled dose, and through the required apheresis-based treatment process.

    • Do not administer in combination with another antineoplastic therapy when monotherapy is required.
    • Follow FDA-approved dosing and administration labeling.
    • Confirm hematology/oncology assessment that the member is an appropriate candidate for apheresis.
    Not achieving a complete response after 2 cycles of standard chemotherapy
    Chemorefractory diseaseNot achieving a complete response after 1 cycle of standard chemotherapy for relapsed disease
    Qualifying alternativeFor Philadelphia chromosome-negative disease, second or greater bone marrow relapse also qualifies
    The member is 25 years or younger
    <=25 years
  9. Performance status: The member has a Karnofsky or Lansky performance score of at least 50% or an ECOG performance score of 0-3Karnofsky/Lansky >=50% or ECOG 0-3
  10. Diagnosis: The member has B-cell precursor acute lymphoblastic leukemia
  11. Philadelphia chromosome-negative disease

    • Refractory disease: Primary refractory disease or chemorefractory disease

      No complete response after 2 cycles of standard chemotherapy, or after 1 cycle for relapsed disease

    • Relapse: Second or greater bone marrow relapse
  12. Philadelphia chromosome-positive disease

    • TKI history: Contraindication, intolerance, or failure of two prior lines of tyrosine kinase inhibitor therapy2 prior TKI lines
    • Post-transplant relapse: Any bone marrow relapse after allogeneic stem cell transplantation
  13. B-cell lymphoma

    • Age: The member is 18 years or older>=18 years
    • Performance status: The member has an ECOG performance status of 0 or 1ECOG 0-1
    • Covered diagnosis: The member has diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, diffuse large B-cell lymphoma arising from follicular lymphoma, or follicular lymphoma
    • Prior therapy: Tisagenlecleucel will be used as third-line or subsequent therapyThird-line or later